![](/images/graphics-bg.png)
Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study
Joint Authors
Cakir, Akin
Erden, Burak
Bolukbasi, Selim
Baş, Emine
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-10-31
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Purpose.
To compare one-year treatment outcomes of intravitreal aflibercept (IVA) and intravitreal ranibizumab (IVR) for treatment of myopic choroidal neovascularization (mCNV).
Methods.
The medical records of a total of 30 eyes diagnosed with mCNV and underwent IVA or IVR treatment for a minimum one-year follow-up were studied retrospectively.
All the subjects had an axial length >26 mm and received a 1 + PRN (pro re nata) regimen IVA or IVR.
Best-corrected visual acuity (BCVA) and central macular thicknesses (CMT) on optical coherence tomography were evaluated before and after treatment.
Results.
There were 12 eyes in IVA group, with a mean age of 60.0 ± 10.2 years.
The mean BCVA significantly improved from baseline 1.54 ± 0.76 to 0.85 ± 0.61 and the mean CMT significantly decreased from baseline 384.3 ± 119.1 μm to 305.9 ± 75.4 μm at Month 12 (p:0.024 and p:0.011, respectively).
There were 18 eyes in IVR group, with a mean age of 57.4 ± 13.1 years.
The mean BCVA improved from baseline 1.14 ± 0.90 to 1.04 ± 0.93 and the mean CMT significantly decreased from baseline 366.5 ± 102.3 μm to 323.6 ± 103.6 μm at Month 12 after IVR (p:0.345 and p:0.011, respectively).
There was no significant difference between the groups in CMT changes in the study period (p:0.178), but IVA resulted in significantly better final visual gain (0.69 versus 0.09; p:0.006).
Conclusions.
Both IVA and IVR treatment modalities resulted in similar anatomical outcomes but IVA had better visual outcomes in treatment of mCNV.
American Psychological Association (APA)
Erden, Burak& Bolukbasi, Selim& Baş, Emine& Cakir, Akin. 2019. Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study. Journal of Ophthalmology،Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1186313
Modern Language Association (MLA)
Erden, Burak…[et al.]. Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study. Journal of Ophthalmology No. 2019 (2019), pp.1-6.
https://search.emarefa.net/detail/BIM-1186313
American Medical Association (AMA)
Erden, Burak& Bolukbasi, Selim& Baş, Emine& Cakir, Akin. Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study. Journal of Ophthalmology. 2019. Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1186313
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1186313